Physician profile
Geva E Mannor
NPI 1730140849
$1,689.68
in general payments reported to CMS, 2019-2025
13 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $17.24 · 2021: $324 · 2022: $16.49 · 2023: $400 · 2024: $190 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $366.35 | 2019-2021 | |
| Horizon Therapeutics Plc | $351.91 | 2021-2023 | Tepezza |
| Amgen INC. | $287.15 | 2025 | Tepezza |
| Abbvie INC. | $245.37 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $161.82 | 2023-2024 | Stellaris, Envista Mx60 Iol, Vyzulta |
| Apellis Pharmaceuticals, INC. | $129.14 | 2024-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $27.55 | 2025 | Yutiq |
| Mallinckrodt Hospital Products INC. | $25.92 | 2023 | Acthar |
| Oyster Point Pharma, INC. | $21.59 | 2024 | Tyrvaya |
| Immunocore Limited | $20.19 | 2024 | Kimmtrak |
| Thea Pharma INC. | $18.96 | 2025 | Iyuzeh |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geva Mannor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.